WEBINAR NOTES FROM AUGUST 23, 2025:

PLASMALOGENS – PART 2: The Secret Lipid that Shapes Health & Disease

These are the notes I move through during the webinar video. You can view the video here:



Plasmalogens are a special type of phospholipid—the fats that make up our cell membranes. They act as protectors against oxidative stress, help organize cholesterol and signaling in membranes, and are especially concentrated in the **brain, heart, and immune system.**

👉 *Think of them as the body's built-in membrane guardians and signal organizers.*

Myelin – Quick Facts

- Myelin is a fatty, insulating sheath that wraps around nerve fibers (axons).
- It allows electrical impulses to travel quickly and efficiently between nerve cells.
- Composed mostly of lipids (about 70–80%) and proteins.
- Critical for normal brain and nervous system function: movement, sensation, cognition.

- Development: infants are born with little myelin; progressive myelination underlies milestones like focusing, speaking, walking.
- Damage or loss of myelin (demyelination) occurs in conditions like **multiple sclerosis**, slowing or blocking nerve signal transmission.

Myelin & Childhood Development

- **Myelin = insulation** around nerve fibers → allows electrical signals to travel fast and efficiently.
- **At birth:** little myelin → newborns can't focus, coordinate movement, or process complex input.
- **Infancy–early childhood:** progressive **myelination of brain regions** drives milestones:
    - Visual pathways → focusing, recognizing faces.
    - Motor pathways → rolling, crawling, walking.
    - Language areas → babbling, then speaking.
    - Prefrontal regions → attention, planning, impulse control.
- **By adolescence:** myelin networks mature, enabling higher cognition and social/emotional regulation.

👉 **Bottom line:** *Each leap in early development reflects a new wave of myelin growth — it's the brain's accelerator pedal for learning and function.*

Plasmalogens, Lipid Rafts & Cholesterol Transport

- **Lipid rafts** are specialized microdomains in cell membranes rich in cholesterol, sphingolipids, and proteins. They act like "platforms" for cell signaling, trafficking, and membrane stability.
- **Plasmalogens** are enriched in these lipid rafts, where they:
    - Help organize and stabilize membrane structure.
    - Influence which proteins cluster in the raft, thus modulating signaling pathways (immune, neurological, etc.).
- **Cholesterol transport:** Plasmalogens interact with cholesterol, helping to regulate its distribution within membranes. Proper plasmalogen levels keep cholesterol mobile and functional instead of rigid or "stuck."
- In the **brain**, this means:
    - Better membrane fluidity and signaling between neurons.
    - More efficient neurotransmission.
    - Support for myelin formation (which itself requires both cholesterol and plasmalogens).
- When plasmalogen levels fall, lipid rafts lose integrity, cholesterol handling falters, and signaling becomes dysfunctional—this is seen in Alzheimer's, MS, and other neurodegenerative conditions.

👉 In short: **Plasmalogens are the architects and caretakers of lipid rafts**, keeping cholesterol in the right place at the right time for healthy signaling and myelin integrity.

Brain & Cholesterol – Key Points

- **Brain makes its own cholesterol:**
  - The **blood–brain barrier (BBB)** blocks circulating cholesterol (carried by LDL, HDL, etc.) from directly entering the brain.
  - Therefore, **~20–25% of the body's total cholesterol is synthesized inside the brain** by astrocytes, neurons, and especially oligodendrocytes (which make myelin).
- **Why this matters:**
  - Brain cholesterol is essential for **synapse formation, neurotransmitter release, and myelin production**.
  - Cholesterol in the brain is more "stable" than in the rest of the body—its turnover is slow (half-life can be *years*).
  - Disturbances in brain cholesterol metabolism (not blood cholesterol) are implicated in Alzheimer's and other neurodegenerative diseases.
- **LDL & Alzheimer's connection:**
  - High blood LDL doesn't cross the BBB, but **systemic lipid dysfunction** can mirror or exacerbate brain lipid issues.
  - **APOE (esp. APOE4)** is the cholesterol transporter *within the brain*; faulty APOE4 handling leads to poor cholesterol recycling, impaired synapse repair, and amyloid accumulation.
  - Plasmalogens help stabilize lipid rafts and cholesterol distribution, partly compensating for APOE4 problems. (I argue with the "partly" part – see further down – having adequate plasmalogens *negates* the genetic risk!)

👉 **Bottom line:**

High blood LDL is a risk marker, but the real story is that the **brain must manage its own cholesterol supply**. When brain lipid transport or plasmalogen support falters, neurons and myelin suffer—even if blood cholesterol is high.

Statins & Brain Cholesterol

- **Mechanism:** Statins inhibit **HMG-CoA reductase**, the rate-limiting enzyme for cholesterol synthesis. Their main effect is in the liver, reducing circulating LDL.
- **Brain impact:**
  - Statins **can cross the blood–brain barrier** to varying degrees (lipophilic ones like simvastatin, atorvastatin, lovastatin more than hydrophilic ones like pravastatin, rosuvastatin).
  - When they do, they may also suppress **brain cholesterol synthesis**, which is normally a self-sufficient, closed system.
- **Consequences:**
  - **Reduced synapse formation and repair** (cholesterol is essential for synaptogenesis).

    - Potential **memory or cognitive side effects** (well-documented anecdotally, supported by some clinical data).
    - Possible impact on **myelin production and maintenance**, since oligodendrocytes need cholesterol for sheathing axons.
- **Why some tolerate them fine:** Not all statins cross the BBB significantly; individual differences in blood–brain barrier permeability, genetics (e.g., APOE type), and baseline plasmalogen/brain lipid status may determine sensitivity.

👉 **Bottom line:** While statins are effective for lowering blood LDL, they can **unintentionally reduce cholesterol synthesis inside the brain** if they cross the BBB — potentially impairing cognition, memory, and myelin maintenance.

APOE4 & Plasmalogens – Game-Changer Insight

- **APOE4**: A genetic variant strongly associated with higher Alzheimer's risk. It impairs lipid transport in the brain, leading to poor cholesterol recycling, amyloid buildup, and synapse loss.
- **Goodenowe's finding:** High, optimal plasmalogen levels **completely neutralize** the increased Alzheimer's risk conferred by APOE4.
- **Translation:** Genetics isn't destiny. Even the "dreaded APOE4" can be overridden if plasmalogen levels are maintained.
- **Why:** Plasmalogens stabilize lipid rafts, improve cholesterol trafficking, and support myelin and synapse integrity—essentially compensating for APOE4's weaknesses.

👉 **Bottom line:** *Plasmalogens knock APOE4 out of the equation*. Alzheimer's risk can be mitigated, regardless of genotype.

Plasmalogen Precursors by Condition

Legend

- **Primary** = first pick based on tissue targeting
- **Stack** = consider adding for complementary support

Alzheimer's disease (AD)

- **Primary: ProdromeNeuro** (omega-3/DHA plasmalogen precursor) → targets **gray matter & synapses**; supports reverse cholesterol transport and keeps brain amyloid low. Prodrome+1
- **Stack: Glia** (white matter/myelin stability) ± **Neuro-PC+** (PC + fat-soluble vitamins + Neuro plasmalogens) for cholinergic membrane support. Prodrome
- **Notes:** Low plasmalogens correlate with AD; Goodenowe's work shows plasmalogens outperform APOE4 as a risk marker and interact with APOE status. PMCPubMedApollo Health

---

Parkinson's disease (PD)

- **Primary: ProdromeNeuro** → synaptic/neuromuscular junction function; gray-matter emphasis. Prodrome
- **Stack: Glia** for white-matter stability; **Neuro-PC+** if you want added PC and fat-soluble vitamin membrane support. Prodrome+1
- **Notes:** Rationale is mechanistic (synapse integrity, membrane signaling); human PD outcome data are still emerging. Frontiers

---

Lewy Body Dementia (LBD)

- **Primary: ProdromeNeuro** → synaptic/gray-matter focus. Prodrome
- **Stack: Glia** for white matter; **Neuro-PC+** for membrane/PC support. Prodrome+1
- **Notes:** Similar synaptic stress/alpha-synucleinopathy logic as PD; evidence base is mechanistic/early translational. MDPI

Amyotrophic Lateral Sclerosis (ALS)

- **Primary: Combo: Neuro + Glia** → motor neuron membranes (gray-matter/synapse) **and** myelin/white-matter support. Prodrome+1
- **Stack: PC+** (pick Neuro-PC+ or Glia-PC+) when broader membrane resilience and fat-soluble vitamin support are desired. Prodrome
- **Notes:** Targeting is biochemical (membrane repair, oxidative stress); clinical data specific to ALS remain limited. PMC

Multiple Sclerosis (MS)

- **Primary: ProdromeGlia** (omega-9 plasmalogen precursor) → targets **white matter/myelin**; supports calm/focus. Prodrome+1
- **Stack: Glia-PC+** for added **phosphatidylcholine + CoQ10 + D3/E/K2** with Glia plasmalogens; consider adding **Neuro** if cognitive/synaptic complaints are prominent. Prodrome
- **Notes:** MS shows reduced plasmalogens; Goodenowe discusses demyelination prevention with precursors. Dr. Goodenowe+1

Autism

- **Primary: ProdromeGlia** → **white-matter/myelin restoration** emphasis (autism programs at Moose Jaw center). ProdromeDr. Goodenowe
- **Stack: Glia-PC+** (featured in Goodenowe's autism outreach) for added PC + fat-soluble vitamins. Dr. GoodenoweProdrome
- **Notes:** Messaging from Goodenowe emphasizes function/quality-of-life support; not a "cure." Dr. Goodenowe

---

Cancer *(signal & risk context, not treatment claims)*

- **Focus: Restore global plasmalogen status** (start with **Glia** or **Neuro** based on individual profile; consider **PC+** for broader membrane support). Evidence links **low plasmalogens** with increased cancer risk/biomarkers (e.g., breast/ovarian), but

disease-treatment guidance is not established. Dr. GoodenoweMDPIBioMed Central

- **Notes:** Historic literature on **alkylglycerols** (SLO) shows adjunct/immune effects, but this differs chemically from Prodrome's targeted precursors. Use **ProdromeScan** to individualize. PMCMDPIProdrome

---

Quick Product Targets (at a glance)

- **ProdromeNeuro** = **DHA plasmalogen precursor**, **gray matter & synapses**, reverse cholesterol transport, amyloid control. Prodrome
- **ProdromeGlia** = **omega-9 plasmalogen precursor**, **white matter & myelin** (brain, heart membranes); calming/focus. Prodrome
- **PC+ line (Glia-PC+ / Neuro-PC+)** = **phosphatidylcholine + fat-soluble vitamins plus** respective plasmalogens for comprehensive membrane support. Prodrome+1

Practical tip

If you have **ProdromeScan** access (you do!), let the biomarker pattern drive the stack (e.g., low PlsEtn species, low omega-9 markers → emphasize **Glia**; low DHA-plasmalogen species or synaptic deficits → emphasize **Neuro**). Prodrome

Compliance note: Prodrome states that claims are educational and products are **not validated for clinical use**; use standard professional judgment and disclosures. Prodrome

PLASMALOGENS & CANCER:

Dr. Dayan Goodenowe returns to Vital Signs with Brendon Fallon to reveal systems for averting cancer risk, informed by his deep examination of the biochemistry of health and disease:

"Plasmalogens are … ether lipids. They're molecules that we can't get from our diet; our body makes them. The only time we get them environmentally is through … mother's milk, during breastfeeding. … Twenty to thirty percent of your brain; and 50 percent of your heart muscle is plasmalogens. … When plasmalogen levels are low, the risk of cancer goes way up."

CANCER

Plasmalogens, HDL, and Cancer – Key Insights

1. **Mandel et al., 1998 discovery**
    - They showed that when cell membranes are **deficient in plasmalogens**, HDL (the so-called "good cholesterol") cannot effectively **export cholesterol out of cells**.

    - When plasmalogens were restored, **HDL efflux normalized**.
    - This makes plasmalogens *gatekeepers* for HDL's cholesterol-clearing role.
2. **Why this matters for cancer**
    - **Cancer cells often have faulty mitochondria** → they rely on **glucose (glycolysis)** for energy (the Warburg effect).
    - These cells also show **lipid membrane and cholesterol dysregulation**. If HDL cannot remove excess cholesterol, membranes become rigid and dysfunctional.
    - Dysfunctional membranes impair signaling, allow unchecked growth signals, and worsen oxidative stress.
    - Thus, **low plasmalogens = poor cholesterol efflux = cellular environment ripe for malignant transformation.**
3. **Plasmalogens as the nexus**
    - Plasmalogens don't just sit in membranes; they **enable cholesterol traffic** in and out.
    - By restoring plasmalogens, you restore HDL's ability to clean up excess cholesterol.
    - This contributes to **normalizing cell signaling, reducing oncogenic stress, and supporting immune surveillance.**

Bottom Line (Whitcomb's Point)

- *"This is the nexus of cancer."*
- Translation: If HDL can't do its job without plasmalogens, then **plasmalogen deficiency is a critical link in cancer development.**
- **Restoring plasmalogens = restoring HDL function = breaking a vicious cycle that fuels cancer.**